Skip to content

Efficacy and safety of fractional 1064-nm picosecond laser on skin quality

Efficacy and safety of fractional 1064-nm picosecond laser on skin quality

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230417008
Enrollment
30
Registered
2023-04-17
Start date
2023-04-11
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy person fractional 1064-nm picosecond laser,skin quality

Interventions

Patient were treated with fractional 1064-nm picosecond laser 2 sessions every 4 weeks. Then they were instructed to follow up at 1, 3, and 6 months after the treatment.
Experimental Device

Sponsors

Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Lead Sponsor
Lasermed Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All
Age
35 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 35 to 45 years old 2. Were diagnosed with mild to moderate wrinkle and skin laxity by dermatologist

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant, lactating, and postpartum within 1 year 2. Patients who taking oral isotretinoin within 1 year 3. Patients with other skin disease, or having infection at the area of face 4. Immunocompromised patients 5. Patients with hypertrophic scar or keloid 6. Patients with history of Cushing syndrome or Ehlers-Danlos syndromd 7.Patients with cancers or skin cancers 8.Patients with mental disorders 9.Patiens with laser, botox or facial treatment within 6 months 10. patient with herpes simplex infection

Design outcomes

Primary

MeasureTime frame
Wrinkle and Texture Baseline, 1, 2,4 7 months Antera

Secondary

MeasureTime frame
Skin elasticity Baseline, 1, 2, 4, 7 months Cutometer,Skin hydration Baseline, 1, 2, 4, 7 months corneometer,Melanin and erythema index Baseline, 1, 2, 4, 7 months mexameter,sebum Baseline, 1, 2, 4, 7 months sebumeter,Pain score Baseline, 1, 2, 4, 7 months Visual Analog Scale,Safety Baseline, 1, 2, 4, 7 months Adverse events,Patient evaluation Baseline, 1, 2, 4, 7 months quatile scale,Doctor evaluation Baseline, 1, 2, 4, 7 months quatile scale

Countries

Thailand

Contacts

Public ContactWoraphong Manuskiatti

Faculty of Medicine Siriraj Hospital, Mahidol University.

doctorlaser@gmail.com664194333

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026